ENDOLEASE

The First Implantable Platform Technology for Superselective Intra-Arterial Drug Delivery

Common methods of drug administration include oral ingestion or intravenous injection, which results in systemic effects on the body.

Unfortunately, the adverse reactions often outbalance the therapeutic use and lead to dose-limiting side effects (e.g. chemotherapeutics).

Systemic drug administration is the crucial dilemma in Pharmacology!

Status Quo

Disruptive Innovation

A patented tubular implant which is based on biodegradable FDA approved materials and positioned into an artery.
ENDOvascular reLEASE of drugs into bloodstream and hence increasing efficacy although minimizing adverse reactions.
Paving the way for drugs limited by systemic side effects.

Various Applications

Myocardial Infarction

Cardio-protective drugs such as Fingolimod can not be administered systemically after infarction. The ENDOLEASE-System releases the agents directly to the targeted tissue to stop inflammatory remodelling processes without systemic immunosuppression.

+ 0

Potential Patients in Germany P.A.

Stroke

After a stroke patients often suffer from oedema with subsequent increasing intracranial pressure. Glucocorticoids with Bortezomib would prevent this mechanism but are not applicable due to systemic side effects. Treating with the ENDOLEASE-System protects from the described vicious circle.

+ 0

Potential Patients in Germany P.A.

Cancer

The dose of chemotherapeutics is limited by severe side effects. An example is the treatment of breast cancer with Doxorubicin and cardiotoxicity as a side effect. The ENDOLEASE-System allows treating solid tumours with higher doses and minimal adverse reactions.

+ 0

Potential Patients in Germany P.A.